Merrimack Pharma (MACK) – FDA
-
Merrimack (MACK) Reports Ipsen Announced FDA Approval of Onivyde
-
Merrimack Pharma (MACK) Confirms Ipsen's Onivyde Regimen Demonstrated Statistically Significant Improvement in OS in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MACK Stock Lookup